Articles related to CHEMOTHERAPY

The recent phase 3 trial has demonstrated the potential of amivantamab as a first-line treatment option for patients with advanced NSCLC with EGFR exon 20 insertions. The combination of amivantamab and chemotherapy significantly improved progression-free survival compared to chemotherapy alone.

The study underscores the potential of perioperative durvalumab in combination with neoadjuvant chemotherapy to significantly improve event-free survival and pathological complete response in patients with resectable NSCLC.

The discovery that chemotherapy-induced cognitive impairment, or “chemobrain,” may be linked to an excess of calcium inside cells opens new avenues for potential therapies. This breakthrough could lead to treatments that restore cognition in patients experiencing these symptoms.

This recent study suggests that systemic treatment with chemotherapy plus immunotherapy may allow patients with muscle-invasive bladder cancer (MIBC) to avoid radical cystectomy.

Test your knowledge and clinical acumen with this quiz, featuring a case study on chemotherapy regimens for metastatic adenocarcinoma of the colon.

Explore how high-dose hyperfractionated thoracic radiotherapy is setting new standards in LS-SCLC treatment.